Cellular retinoic acid-binding protein 1 is a protein that in humans is encoded by the CRABP1gene.[5][6]
CRABP1 is assumed to play an important role in retinoic acid-mediated differentiation and proliferation processes. It is structurally similar to the cellular retinol-binding proteins, but binds only retinoic acid. CRABP1 is constitutively expressed and is believed to have different functions in the cell than the related CRABP2.[6]
Figure 1. An overview of retinoid transfer by CRABP. R = Retinoic acid, RAR = retinoic acid receptor, RXR = Retinoic X receptor, RRE = retinoid response element. CRABP binds to retinoic acid and transports it to the nucleus where binding with RAR or RXR homodimers or heterodimers further regulates RREs to regulate transcription events on DNA.[7]
Figure 2. Retinoic acid (RA) is processed from vitamin A to bind to fatty acid binding protein (FABP5) along with CRABP to associate with the binding to DNA to mediate pathways. RA binds with CRABP to mediate further action with retinoic acid receptor (RAR) on DNA for pathway mediation as well.[8]
Figure 3. Image of the domain locations for CRABP1. The nuclear localization signal (NLS) is at position 21-31 and the retinoic acid binding site (RBS) is at position 132-134.[9]
CRABP1 binds to retinoid acid and helps to transport it into the nucleus (Figure 1). Both CRABP1 and CRABP2 perform this activity. The retinoic acid molecule is then released and further bound to retinoic acid receptor (RAR) and the retinoid X receptor (RXR) as homodimers or heterodimers. This complex then further binds to retinoic acid response elements (RARE) on DNA that regulates transcription of retinoid acid dependent null genes.[10] The domains for the nuclear localization and the retinoic acid binding are shown in Figure 3.
CRABP1 has been found to be involved in multiple cancer proliferation pathways. CRABP1 activates the extracellular signal-regulated kinase, ERK1 and ERK2 kinases, which are involved in the cell cycle. CRABP1 activity can thus extend the cell cycle, e.g. in embryonic and neural stem cells. Knockout mice without CRABP1 showed increased neural stem cell proliferation and thus hippocampus neurogenesis. Furthermore, learning and memory were improved in knockout mice, as measured by the Morris water maze test and an object recognition task.[11]
CRABP1 is also involved in cancer cell apoptosis. trans-retinoic acid was considered a [null therapeutic target for cancer] as a ligand of CRABP1.[12] It was observed that CRABP1 regulated ERK1/2) which in turn activates the protein phosphatase 2A (PP2A) that induces apoptosis of cancer cells and lengthens the cell cycle of embryonic stem cells. PP2A activity promotes the stem cells renewal ability during the differentiation process. When CRABP1 was knocked down the apoptotic induction ability was also removed and allowed for cell proliferation. The re-expression of CRABP1 in CRABP1 null cells brought back the induced apoptotic activity. Thus CRABP1 may be used as a therapeutic target along with trans-retinoic acid for apoptotic activity within cancer cells.[12] Figure 2 illustrates both pathways of retinoic acid binding to CRABP for cell proliferation and apoptotic activity.
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Flagiello D, Apiou F, Gibaud A, Poupon MF, Dutrillaux B, Malfoy B (Jun 1997). "Assignment of the genes for cellular retinoic acid binding protein 1 (CRABP1) and 2 (CRABP2) to human chromosome band 15q24 and 1q21.3, respectively, by in situ hybridization". Cytogenetics and Cell Genetics. 76 (1–2): 17–8. doi:10.1159/000134502. PMID9154115.
Eller MS, Oleksiak MF, McQuaid TJ, McAfee SG, Gilchrest BA (February 1992). "The molecular cloning and expression of two CRABP cDNAs from human skin". Experimental Cell Research. 198 (2): 328–36. doi:10.1016/0014-4827(92)90387-N. PMID1309505.
Ong DE (December 1987). "Cellular retinoid-binding proteins". Archives of Dermatology. 123 (12): 1693–1695a. doi:10.1001/archderm.123.12.1693. PMID2825608.
Liu W, Hellman P, Li Q, Yu WR, Juhlin C, Nordlinder H, Rollman O, Akerström G, Törmä H, Melhus H (December 1996). "Biosynthesis and function of all-trans- and 9-cis-retinoic acid in parathyroid cells". Biochemical and Biophysical Research Communications. 229 (3): 922–9. doi:10.1006/bbrc.1996.1903. PMID9005841.
Kreutz M, Fritsche J, Andreesen R, Krause SW (July 1998). "Regulation of cellular retinoic acid binding protein (CRABP II) during human monocyte differentiation in vitro". Biochemical and Biophysical Research Communications. 248 (3): 830–4. doi:10.1006/bbrc.1998.9058. PMID9704013.
Huang Y, de la Chapelle A, Pellegata NS (May 2003). "Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma". International Journal of Cancer. 104 (6): 735–44. doi:10.1002/ijc.11006. PMID12640681. S2CID26461955.
Blaese MA, Santo-Hoeltje L, Rodemann HP (December 2003). "CRABP I expression and the mediation of the sensitivity of human tumour cells to retinoic acid and irradiation". International Journal of Radiation Biology. 79 (12): 981–91. doi:10.1080/09553000310001632949. PMID14713576. S2CID37684886.
Won JY, Nam EC, Yoo SJ, Kwon HJ, Um SJ, Han HS, Kim SH, Byun Y, Kim SY (August 2004). "The effect of cellular retinoic acid binding protein-I expression on the CYP26-mediated catabolism of all-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma". Metabolism. 53 (8): 1007–12. doi:10.1016/j.metabol.2003.12.015. PMID15281009.
